CDK8 and cancer: SE inhibitors, such as the BRD4 inhibitor JQ1 [40], cyclin-dependent kinase (CDK)4/6 inhibitor LEE011 [41], and CDK8 inhibitor cortistatin A [42], have shown great potential for suppressing cancer progression by interfering with SE activity.